Results 11 to 20 of about 5,328 (181)

Inhibition of planktonic growth and biofilm formation of Staphylococcus aureus by entrectinib through disrupting the cell membrane

Frontiers in Microbiology, 2023
Over the last few decades, Staphylococcus aureus infection remain a major medical challenge and health concern worldwide. Biofilm formation and antibiotic resistance caused by S.
Shanghong Liu, Shanghong Liu, Yanpeng Xiong, Haitao Xiao, Jinxin Zheng, Zewen Wen, Duoyun Li, Duoyun Li, Qiwen Deng, Qiwen Deng, Zhijian Yu, Zhijian Yu   +11 more
doaj   +1 more source

Docking and Molecular Dynamics Simulation-Based Analysis of Advanced Small-Molecule Kinase Inhibitors Identified pre-let-7 miRNA Binders. [PDF]

Chembiochem
An integrated computational approach evaluating the binding between pre‐let‐7 microRNA and small‐molecule kinase inhibitors (SMKIs) revealed varied pre‐let‐7 binding affinities among the advanced SMKIs. The results justified the characterization of potential RNA targets for kinase inhibitors and small molecules with protein targets in general.
Roy S, Liu Y, Wu P.
europepmc   +2 more sources

Refractory response to entrectinib for ROS‐1 rearranged NSCLC with concurrent de novo TP53 mutation showing good response to CNS lesion, but poor duration of response: A case report

Thoracic Cancer, 2023
Entrectinib, a ROS‐1 inhibitor, has been shown to be effective for patients with ROS‐1 fused NSCLC, and has been established as the standard of care for this population.
Kentaro Ito, Miho Nishio, Kentaro Fujiwara, Yoichi Nishii, Kengo Ushiro, Hiroki Yasui, Osamu Hataji   +6 more
doaj   +1 more source

A case of hepatic dysfunction from crizotinib followed by treatment with entrectinib

Current Problems in Cancer: Case Reports, 2023
Background: Information regarding the safety of entrectinib for previously treated patients and patients with hepatic dysfunction is limited. This is the first case report of treatment modification attributable to hepatic dysfunction caused by crizotinib.
Takahito Mizuno, Satoshi Hagimoto, Takumi Umemura, Mariko Higashikawa, Takamasa Sakai, Kouichi Tanabe, Fumiko Ohtsu, Tetsuya Yamada, Tomoki Kimura   +8 more
doaj   +1 more source

Lethal ventricular arrhythmia due to entrectinib-induced Brugada syndrome: a case report and literature review [PDF]

, 2023
Entrectinib, a multikinase inhibitor of ROS1 and tropomyosin receptor kinases, is recommended to treat ROS1-positive metastatic non-small cell lung cancer (NSCLC).
Futamura, Keisuke, Hase, Tetsunari, Hashimoto, Takahiko, Inden, Yasuya, Ishii, Makoto, Ito, Katsuki, Nakashima, Kuniya, Numaguchi, Atsushi, Okachi, Shotaro, Sakai, Yoshinori, Shibata, Hirofumi, Tanaka, Akihito, Ushijima, Futoshi, Yamamoto, Takanori   +13 more
core   +1 more source

MET kinase inhibitor reverses resistance to entrectinib induced by hepatocyte growth factor in tumors with NTRK1 or ROS1 rearrangements

Cancer Medicine, 2023
Background Entrectinib is an effective drug for treating solid tumors with NTRK gene rearrangement and non‐small cell lung cancer (NSCLC) with ROS1 gene rearrangement.
Yohei Takumi, Sachiko Arai, Chiaki Suzuki, Koji Fukuda, Akihiro Nishiyama, Shinji Takeuchi, Hiroki Sato, Kunio Matsumoto, Kenji Sugio, Seiji Yano   +9 more
doaj   +1 more source

Efficacy of Crizotinib After Entrectinib Resistance Due to MET Polysomy in ROS1-Rearranged NSCLC: A Case Report

JTO Clinical and Research Reports, 2023
Resistance to ROS1 tyrosine kinase inhibitors is inevitable, but it has been unclear whether crizotinib might be effective after the development of entrectinib resistance. We here present a case of ROS1-rearranged NSCLC that responded to crizotinib after
Toshiaki Takakura, MD, Hiroaki Kanemura, MD, MPH, Kazuko Sakai, PhD, Kazuto Nishio, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Hidetoshi Hayashi, MD, PhD   +5 more
doaj   +1 more source

Cost-effectiveness of alternative NTRK testing strategies in cancer patients followed by histology-independent therapy with entrectinib:an analysis of three European countries [PDF]

, 2023
Aim: To explore variations in the cost-effectiveness of entrectinib across different testing strategies and settings. Methods: Four testing strategies where adult cancer patients received entrectinib if they tested positive for NTRK gene fusions compared
Huygens, Simone, Koleva-Kolarova, Rositsa, Nagy, Balázs, Rutten-van Mölken, Maureen, Szilberhorn, László, Vellekoop, Heleen, Versteegh, Matthijs, Wordsworth, Sarah, Zelei, Tamás   +8 more
core   +1 more source

Entrectinib for ROS1‐rearranged non‐small cell lung cancer after crizotinib‐induced interstitial lung disease: A case report

Respirology Case Reports, 2021
Chromosomal rearrangements involving the c‐ros oncogene 1 (ROS1) are identified in approximately 1% of non‐small cell lung cancer (NSCLC) patients. Crizotinib is the first tyrosine kinase inhibitor (TKI) against ROS1‐rearranged NSCLC. G2032R, a secondary
Mai Tanimura, Nobutaka Kataoka, Yusuke Kunimatsu, Rei Tsutsumi, Izumi Sato, Takayuki Nakano, Keiko Tanimura, Takayuki Takeda   +7 more
doaj   +1 more source

The Safety Profiles of Two First-Generation NTRK Inhibitors: Analysis of Individual Case Safety Reports from the FDA Adverse Event Reporting System (FAERS) Database

Biomedicines, 2023
The first-generation tropomyosin receptor kinase (TRK) inhibitors, larotrectinib and entrectinib, represent exciting new developments in cancer treatment that offer relevant, rapid, and long-lasting clinical benefits.
Valerio Liguori, Mario Gaio, Alessia Zinzi, Cecilia Cagnotta, Consiglia Riccardi, Giovanni Docimo, Annalisa Capuano   +6 more
doaj   +1 more source